Zydus and Synthon Partner to Launch Generic Multiple Sclerosis Drug in $637 Million US Market
Key Insights
Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV to commercialize generic Ozanimod capsules for multiple sclerosis (search) treatment in the US market.
Synthon has received tentative FDA approval as one of the first filers and will handle regulatory approval and manufacturing, while Zydus manages US commercialization of the generic version of ZEPOSIA.
The collaboration targets a total addressable market opportunity of approximately $637 million for Ozanimod capsules in the US, with the product eligible for shared 180-day exclusivity upon market entry.
Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules for multiple sclerosis (search) treatment in the US market. The partnership positions both companies to capture a share of the estimated $637 million total addressable market opportunity for Ozanimod capsules in the United States.
Strategic Partnership Structure
Under the terms of the agreement, Synthon will be responsible for obtaining final regulatory approval and thereafter managing the manufacture and supply of the generic Ozanimod capsules, which serve as a generic version of ZEPOSIA. Zydus will handle the commercialization of the product in the US market through its subsidiary operations.
Synthon currently has a pending abbreviated new drug application (ANDA) in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis (search). As one of the first filers, Synthon has received tentative approval within 30 months from the US FDA, making the product eligible for a shared 180-day exclusivity period upon market entry.
Therapeutic Indication and Market Opportunity
ZEPOSIA (Ozanimod) is a sphingosine 1-phosphate receptor (search) modulator indicated for the treatment of relapsing forms of multiple sclerosis (search), including clinically isolated syndrome (search), relapsing-remitting disease (search), and active secondary progressive disease (search) in adults. The drug is also approved for moderately to severely active ulcerative colitis (search) in adults. ZEPOSIA is a trademark of Receptos, LLC (search), a Bristol Myers Squibb (search) company.
The total addressable market opportunity for Ozanimod capsules in the US is approximately $637 million, according to IQVIA MAT July 2025 data cited by the companies.
Executive Perspectives
"This collaboration with Synthon enables us to bring this important treatment to the US market," said Punit Patel, President and Chief Executive Officer of Zydus Pharmaceuticals (USA) Inc. "This collaboration reinforces our strategic focus on advancing care in therapeutic areas and reflects our commitment to making essential medicines more accessible to patients."
Anish Mehta, Chief Executive Officer of Synthon BV, emphasized the partnership's strategic value: "This collaboration with Zydus for Ozanimod capsules continues to underscore our proven expertise in developing first-to-market, complex generic products. We are pleased to strengthen our partnership with Zydus as we continue advancing our strategic commitment to expanding access to essential medicines."